hCG Clinical Trial
Official title:
hCG Concentration in Peripheral Maternal Blood After Embryo Transfer, Ongoing Pregnancy
Verified date | January 2021 |
Source | IVI Vigo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
hCG is a hormone produced very early by the embryo, but not by the oocyte. It has a pivotal role in the trophoblast differentiation, and embryo implantation as well as the corpus luteum support. In spite of its well-known role, the literature about it is scarce. The aim of this retrospective study is to evaluate the relationship between the hCG concentration in peripheral maternal blood measured 11 days after embryo transfer, embryo morphokinetics pattern and the abortion and ongoing pregnancy rates. We will study patients having transference of blastocyst cultured in time lapse monitored incubators and will check all the morphokinetics parameters with the IVI database.
Status | Completed |
Enrollment | 300 |
Est. completion date | June 25, 2019 |
Est. primary completion date | June 25, 2019 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years to 32 Years |
Eligibility | Inclusion Criteria: - Donors age < 32. - IMC< 30kg/m2. - Antral follicle count higher than 8. - Single Blastocyst transference. - 5% oxygen embryo culture, - time-lapse monitoring incubation KID embryos. Exclusion Criteria: - Müllerian anomalies, - Hydrosalpinx. - Any indication of oocyte vitrification. - Severe male factor. - Embryos transferences where a tenaculum was required, or more than one attempt was needed. |
Country | Name | City | State |
---|---|---|---|
Spain | IVI Vigo | Vigo | Pontevedra |
Lead Sponsor | Collaborator |
---|---|
IVI Vigo | Instituto Valenciano de Infertilidad, IVI VALENCIA |
Spain,
Basile N, Nogales Mdel C, Bronet F, Florensa M, Riqueiros M, Rodrigo L, García-Velasco J, Meseguer M. Increasing the probability of selecting chromosomally normal embryos by time-lapse morphokinetics analysis. Fertil Steril. 2014 Mar;101(3):699-704. doi: 10.1016/j.fertnstert.2013.12.005. Epub 2014 Jan 11. — View Citation
Domínguez F, Gadea B, Esteban FJ, Horcajadas JA, Pellicer A, Simón C. Comparative protein-profile analysis of implanted versus non-implanted human blastocysts. Hum Reprod. 2008 Sep;23(9):1993-2000. doi: 10.1093/humrep/den205. Epub 2008 Jun 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Researchers pretend to correlate the quality of the trophoectoderm and the embryo morphokinetics time with the hCG concentration after 13 days of embryo transfer, and also the implantation and the ongoing pregnancy rate. | • Clinical pregnancy: when the maternal serum levels of ß-hCG are higher than 10 UI/L, between 14 and 16 days after the fertilization and the presence of a gestational sac can be appreciated by ultrasound scan a week later (21-23 days after fertilization) | Since 2013 to april 2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02427529 -
Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)
|
Phase 1/Phase 2 | |
Completed |
NCT02763176 -
Measuring hCG Levels in Pregnant Women
|
||
Completed |
NCT01390207 -
Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles
|
Phase 2/Phase 3 | |
Completed |
NCT05340010 -
Administration of Human Chorionic Gonadotrophin Before Secretory Transformation of Frozen-thawed Embryo Transfer Cycles
|
Phase 4 | |
Completed |
NCT04417569 -
A Proof of Concept Study of Serum Progesterone Levels for IVF/ICSI Following HCG Trigger for Oocyte Maturation
|
||
Completed |
NCT03495609 -
Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers
|
Phase 4 |